Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in severe acute urticaria
NCT02191072Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Jul 2014
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of omalizumab in acute urticaria, sponsored by National Taiwan University Hospital. Primary endpoint: Urticaria Activity Score at 1 hour. Status: unknown.
02
Drugs
omalizumab
03
Conditions
acute urticaria
Beyond the preview
Go deeper on NCT02191072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02191072.